Review Article
Cardioprotection: A Review of Current Practice in Global Ischemia and Future Translational Perspective
Table 4
Examples of promising therapeutic approaches targeting ischemia reperfusion injury. Adapted from [
42].
| Intervention | Target | Potential downside | Stage | Reference |
| Fibrinogen split product B15–42 | VE Cadherin | Unclear | Preclinical | [35, 36, 43, 48, 49, 53, 54, 66] | Cingulin derived sequence GRRPGGISGG | RhoAGTPase and VE Cadherin | Unclear | Preclinical | [35] | TAK-242 | TLR4 | Immunosuppression | Phase II clinical trial | [60, 67] | Cyclosporine | Cyclophilin/mPTP | Immunosuppression | Phase II clinical trial | [58] | PHD inhibitor | Oxygen sensing PHD enzyme, HIF stabilization | Unclear | Phase II clinical trial | [61, 63] | Ischemic preconditioning | Multiple | Unclear | Phase II clinical trial | [61, 68] | Ischemic postconditioning | Multiple | Unclear | Phase II clinical trial | [69] | Remote ischemic conditioning | Multiple | Unclear | Phase II clinical trial | [70] | Endothelin blockers | Endothelin A receptor/Na+/H+ exchange | Hypotension | Phase II clinical trial | [55, 71] |
|
|